«

»

Difficulties Of Single Monoclonal Antibody Treatment Of SARS-CoV-2: The Sotrovimab Experience In Australia

Rockett et al. demonstrate that resistance to sotrovimab as a monotherapy rises rapidly in treated patients.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive